1217756-07-4Relevant academic research and scientific papers
Design, synthesis, and fungicidal activities of imino diacid analogs of valine amide fungicides
Sun, Man,Yang, Hui-Hui,Tian, Lei,Li, Jian-Qiang,Zhao, Wei-Guang
, p. 5729 - 5731 (2015/11/24)
The novel imino diacid analogs of valine amides were synthesized via several steps, including the protection, amidation, deprotection, and amino alkylation of valine, with the resulting structures confirmed by 1H and 13C NMR and HRMS. Bioassays showed that some of these compounds exhibited good fungicidal activity. Notably, isopropyl 2-((1-((1-(3-fluorophenyl)ethyl)amino)-3-methyl-1-oxobutan-2-yl)amino)propanoate 5i displayed significant levels of control, at 50%, against Erysiphe graminis at 3.9 μM as well as a level of potency very similar to the reference azoxystrobin, which gave 60% activity at this concentration. The present work demonstrates that imino diacid analogs of valine amides could be potentially useful key compounds for the development of novel fungicides against wheat powdery mildew.
3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists
Hipskind, Philip A.,Howbert, J. Jeffry,Bruns, Robert F.,Cho, Steven S. Y.,Crowell, Thomas A.,Foreman, Mark M.,Gehlert, Donald R.,Iyengar, Smriti,Johnson, Kirk W.,Krushinski, Joseph H.,Li, Dominic L.,Lobb, Karen L.,Mason, Norman R.,Muehl, Brian S.,Nixon, James A.,Phebus, Lee A.,Regoli, Domenico,Simmons, Rosa M.,Threlkeld, Penny G.,Waters, Diane C.,Gitter, Bruce D.
, p. 736 - 748 (2007/10/03)
Early structure-activity studies on racemic tryptophan ester and amide NK- 1 antagonists 5-7 led to the discovery that the potency of the series could be markedly increased by moving the carbonyl function in these molecules to an off-chain position as in the 3-aryl-1,2-diacetamidopropane 9. Further medicinal chemistry incorporating this change resulted in the discovery of a novel series of highly potent aryl amino acid derived NK-1 antagonists of the R stereoisomeric series (IC50's = 100 pM to >5 μM). Compounds in this series were shown to be competitive antagonists using an in vitro NK-1 smooth muscle assay, and this data correlated well with observed human NK-1 binding affinities. Two of these agents, (R)-25 and (R)-32, blocked intrathecal NK-1 agonist-driven [Ac-[Arg6, Sar9, Met(O2)11]-substance P 6-11 (Ac-Sar9)] nociceptive behavior in mice. Both compounds potently blocked the neurogenic dural inflammation following trigeminal ganglion stimulation in the guinea pig after intravenous administration. Further, upon oral administration in this model, (R)-32 was observed to be very potent (ID50 = 91 ng/kg) and have a long duration of action (>8 h at 1 μg/kg). Compound (R)-32, designated LY303870, is currently under clinical development as an NK-1 antagonist with a long duration of action.
